SSelectStock
Sign in

ZYDUSLIFEZydus Lifesciences Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

1,149.00
0.46%
75Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,13,077.00
P/E22.62
P/B4.21
PEG2.60
ROE %18.32
ROCE %14.60
Debt / Equity0.42
EPS50.12
Revenue Growth %16.20
Profit Growth %8.70
Dividend Yield %0.95
Promoter Holding %75.18
FII Holding %15.14
DII Holding %
Beta0.40

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG80%1,149.001,126.601,203.902.45
BUYConviction 84%

Why buy

  • ROE: 18.3%
  • Debt/Equity: 0.42
  • Promoter holding: 75.2%
  • RSI: 60
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 80%)

Bull case

  • ROE: 18.3%
  • Debt/Equity: 0.42
  • Promoter holding: 75.2%
  • RSI: 60

Bear case

  • Profit growth: 8.7% YoY
  • PEG ratio: 2.60
  • MACD: bearish
  • Volume: 0.7x 20-day average

Key risks

  • Profit growth: 8.7% YoY
  • PEG ratio: 2.60

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,149.00
Stop Loss
₹1,086.15
risk 5.5%
Target 1 (1.5R)
₹1,243.27
+8.2%
Target 2 (3R)
₹1,337.54
+16.4%
Support (20d)
₹1,087.30
Resistance (52w)
₹1,181.50
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹62.85/share
ATR (volatility)
₹25.14
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹25.14). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
67
Technical
71
Momentum
85
Risk (safety)
83

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.